Live
- Woman’s False Claim Sparks Unnecessary Panic
- Locals Report Naxal Activity in Karkala Village
- Mangaluru International Airport Sets New Records in Passenger and Flight Movements
- Where Areca failed, grow Coffee
- Collector Badavath Santosh Reviews Household Survey and Listing Process
- Awareness Session on SHE Team and POCSO Act
- Awareness Program in agricultural College on the Dangers of Drug Abuse for Youth
- 3500-Year-Old Menhir in Kamsanpally Village: A Call for Preservation
- The Role of Artificial Intelligence in Radiology: Transforming Diagnosis and Patient Care
- Hindustan Zinc Ltd. Signs MoU with Rajasthan Government to Invest Rs 36 Crores in Education Development
Natco settles patent litigation with Onyx
Highlights
City-based Natco Pharma on Thursday said it has settled a patent litigation with Onyx Therapeutics Inc in the US over a generic version of Kyprolis, an anti-cancer drug.
Hyderabad: City-based Natco Pharma on Thursday said it has settled a patent litigation with Onyx Therapeutics Inc in the US over a generic version of Kyprolis, an anti-cancer drug.
The company said it has reached a settlement agreement with Onyx Therapeutics Inc related to generic versions of 10mg, 30mg and 60mg of Kyprolis, Natco Pharma said in a regulatory filing.
Natco has tied up with Breckenridge Pharmaceutical Inc to market the product in the US.
Next Story
ADVERTISEMENT
